Johnson Johnson JNJ Secures FDA Priority Review for IMAAVY Targeting FirstofItsKind Indication for Warm Autoimmune Hemolytic Anemia Summit Therapeutics SMMT Stock Is It the Right Time to Invest Q4 2025 Below Expectations CSX Corporation CSX Valuation Assessment Following Robust Shareholder Returns and Q1 2026 Earnings Release NXGL NexGel reports wider than expected Q4 2025 loss but shares advance on positive investor sentiment ITHAW ITHAX quarterly earnings figures are still pending with leadership set to outline growth priorities shortly